HERG: Protein trafficking and potential for therapy and drug side effects

Current Opinion in Drug Discovery and Development

Volumn 13, Issue 1, 2010, Pages 23-30

  Staudacher, Ingo ^a   Schweizer, Patrick A ^a   Katus, Hugo A ^a   Thomas, Dierk ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Acquired long QT syndrome; Action potential prolongation; Arrhythmia; HERG liability; Preclinical risk assessment; Sudden cardiac death

Indexed keywords

ANTIVIRUS AGENT; ARSENIC TRIOXIDE; ATOMOXETINE; CELASTROL; DIGITOXIN; DIGOXIN; FLUOXETINE; KETOCONAZOLE; NEFERINE; OUABAIN; PENTAMIDINE; POTASSIUM CHANNEL HERG; PROBUCOL; RANOLAZINE; SOPHOCARPINE; SOPHORIDINE; UNCLASSIFIED DRUG;

APOPTOSIS; CARDIOTOXICITY; CELL SURFACE; COMPUTER MODEL; DRUG INHIBITION; DRUG SAFETY; ELECTROPHYSIOLOGY; HEART PROARRHYTHMIA; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; RISK ASSESSMENT; SCREENING;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; APOPTOSIS; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; LONG QT SYNDROME; MODELS, MOLECULAR; PROTEIN TRANSPORT; TORSADES DE POINTES;

EID: 73849133705     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Sanguinetti MC, Tristani-Firouzi M: hERG potassium channels and cardiac arrhythmia. Nature (2006) 440(7083):463-469.
2. Morita H, Wu J, Zipes DP: The QT syndromes: Long and short. Lancet (2008) 372(9640):750-763.
3. Roden DM: Repolarization reserve: A moving target. Circulation (2008) 118(10):981-982.
4. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ et al: Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovasc Res (2003) 58(1):32-45.
5. Thomas D, Karle CA, Kiehn J: The cardiac hERG/IKr potassium channel as pharmacological target: Structure, function, regulation, and clinical applications. Curr Pharm Des (2006) 12(18):2271-2283.
6. QT drugs lists by risk groups: Arizona Center for Education and Research on Therapeutics, Tucson, AZ, USA (2009). www.azcert.org/ medical-pros/drug- lists/drug-lists.cfm
7. Thomas D, Kiehn J, Katus HA, Karle CA: Defective protein trafficking in hERG-associated hereditary long QT syndrome (LQT2): Molecular mechanisms and restoration of intracellular protein processing. Cardiovasc Res (2003) 60(2):235-241.
8. Ficker E, Dennis AT, Wang L, Brown AM: Role of cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel hERG. Circ Res (2003) 92(12):e87-e100.
9. Gong Q, Jones MA, Zhou Z: Mechanisms of pharmacological rescue of trafficking-defective hERG mutant channels in human long QT syndrome. J Biol Chem (2006) 281(7):4069-4074.
10. Walker VE, Atanasiu R, Lam H, Shrier A: Co-chaperone FKBP38 promotes hERG trafficking. J Biol Chem (2007) 282(32):23509-23516.
11. Nanduri J, Bergson P, Wang N, Ficker E, Prabhakar NR: Hypoxia inhibits maturation and trafficking of hERG K+ channel protein: Role of Hsp90 and ROS. Biochem Biophys Res Commun (2009) 388(2):212-216.
12. Wang L, Dennis AT, Trieu P, Charron F, Ethier N, Hebert TE, Wan X, Ficker E: Intracellular potassium stabilizes human ether-ago- go-related gene channels for export from endoplasmic reticulum. Mol Pharmacol (2009) 75(4):927-937.
13. Roti EC, Myers CD, Ayers RA, Boatman DE, Delfosse SA, Chan EK, Ackerman AJ, January CT, Robertson GA: Interactions with GM130 during hERG ion channel trafficking. Disruption by type 2 congenital long QT syndrome mutations. J Biol Chem (2002) 277(49):47779-47785.
14. Ficker E, Kuryshev YA, Dennis AT, Obejero-Paz C, Wang L, Hawryluk P, Wible BA, Brown AM: Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol (2004) 66(1):33-44.
15. Cordes JS, Sun Z, Lloyd DB, Bradley JA, Opsahl AC, Tengowski MW, Chen X, Zhou J: Pentamidine reduces hERG expression to prolong the QT interval. Br J Pharmacol (2005) 145(1):15-23.
16. Kuryshev YA, Ficker E, Wang L, Hawryluk P, Dennis AT, Wible BA, Brown AM, Kang J, Chen XL, Sawamura K, Reynolds W et al: Pentamidineinduced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther (2005) 312(1):316-323.
17. Wible BA, Hawryluk P, Ficker E, Kuryshev YA, Kirsch G, Brown AM: HERG-Lite: A novel comprehensive high-throughput screen for drug-induced hERG risk. J Pharmacol Toxicol Methods (2005) 52(1):136-145.
18. Rajamani S, Eckhardt LL, Valdivia CR, Klemens CA, Gillman BM, Anderson CL, Holzem KM, Delisle BP, Anson BD, Makielski JC, January CT: Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol (2006) 149(5):481-489.
19. Guo J, Massaeli H, Li W, Xu J, Luo T, Shaw J, Kirshenbaum LA, Zhang S: Identification of IKr and its trafficking disruption induced by probucol in cultured neonatal rat cardiomyocytes. J Pharmacol Exp Ther (2007) 321(3):911-920.
20. Takemasa H, Nagatomo T, Abe H, Kawakami K, Igarashi T, Tsurugi T, Kabashima N, Tamura M, Okazaki M, Delisle BP, January CT et al: Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome. Br J Pharmacol (2007) 153(3):439-447.
21. Wang L, Wible BA, Wan X, Ficker E: Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking. J Pharmacol Exp Ther (2007) 320(2):525-534.
22. Dennis A, Wang L, Wan X, Ficker E: hERG channel trafficking: Novel targets in drug-induced long QT syndrome. Biochem Soc Trans (2007) 35(Pt 5):1060-1063.
23. Eckhardt LL, Rajamani S, January CT: Protein trafficking abnormalities: A new mechanism in drug-induced long QT syndrome. Br J Pharmacol (2005) 145(1):3-4.
24. Van der Heyden MA, Smits ME, Vos MA: Drugs and trafficking of ion channels: A new pro-arrhythmic threat on the horizon? Br J Pharmacol (2008) 153(3):406-409.
25. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC: A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA (2000) 97(22):12329-12333.
26. Mitcheson JS: Drug binding to hERG channels: Evidence for a "non-aromatic" binding site for fluvoxamine. Br J Pharmacol (2003) 139(5):883-884.
27. Keating MT, Sanguinetti MC: Molecular and cellular mechanisms of cardiac arrhythmias. Cell (2001) 104(4):569-580.
28. Milnes JT, Crociani O, Arcangeli A, Hancox JC, Witchel HJ: Blockade of hERG potassium currents by fluvoxamine: Incomplete attenuation by S6 mutations at F656 and Y652. Br J Pharmacol (2003) 139(5):887-898.
29. Mitcheson JS, Chen J, Sanguinetti MC: Trapping of a methanesulfonanilide by closure of the hERG potassium channel activation gate. J Gen Physiol (2000) 115(3):229-240.
30. del Camino D, Holmgren M, Liu Y, Yellen G: Blocker protection in the pore of a voltage-gated K+ channel and its structural implications. Nature (2000) 403(6767):321-325.
31. Hancox JC, Mitcheson JS: Combined hERG channel inhibition and disruption of trafficking in drug-induced long QT syndrome by fluoxetine: A case-study in cardiac safety pharmacology. Br J Pharmacol (2006) 149(5):457-459.
32. Zhou Z, Gong Q, January CT: Correction of defective protein trafficking of a mutant hERG potassium channel in human long QT syndrome. Pharmacological and temperature effects. J Biol Chem (1999) 274(44):31123-31126.
33. Ficker E, Obejero-Paz CA, Zhao S, Brown AM: The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-go-go-related gene (hERG) mutations. J Biol Chem (2002) 277(7):4989-4998.
34. Kaufman ES, Ficker E: Is restoration of intracellular trafficking clinically feasible in the long QT syndrome? The example of hERG mutations. J Cardiovasc Electrophysiol (2003) 14(3):320-322.
35. FDA: ICH guidance for industry: S7B nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. Press Release (2005): October.
36. Straus SM, Sturkenboom MC, Bleumink GS, Dieleman JP, Van der Lei J, de Graeff PA, Kingma JH, Stricker BH: Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J (2005) 26(19):2007-2012.
37. Shah RR, Hondeghem LM: Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm (2005) 2(7):758-772.
38. Lu HR, Vlaminckx E, Hermans AN, Rohrbacher J, Van Ammel K, Towart R, Pugsley M, Gallacher DJ: Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B guidelines. Br J Pharmacol (2008) 154(7):1427-1438.
39. Pollard CE, Valentin JP, Hammond TG: Strategies to reduce the risk of drug-induced QT interval prolongation: A pharmaceutical company perspective. Br J Pharmacol (2008) 154(7):1538-1543.
40. Hanson LA, Bass AS, Gintant G, Mittelstadt S, Rampe D, Thomas K: ILSI-HESI cardiovascular safety subcommittee initiative: Evaluation of three non-clinical models of QT prolongation. J Pharmacol Toxicol Methods (2006) 54(2):116-129.
41. Yeoung KS, Meanwell NA: Inhibition of hERG channel trafficking: An under-explored mechanism for drug-induced QT prolongation. ChemMedChem (2008) 3(10):1501-1502.
42. Yao X, Anderson DL, Ross SA, Lang DG, Desai BZ, Cooper DC, Wheelan P, McIntyre MS, Bergquist ML, MacKenzie KI, Becherer JD et al: Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model. Br J Pharmacol (2008) 154(7):1446-1456.
43. Haushalter TM, Friedrichs GS, Reynolds DL, Barecki-Roach M, Pastino G, Hayes R, Bass AS: The cardiovascular and pharmacokinetic profile of dofetilide in conscious telemetered beagle dogs and cynomolgus monkeys. Br J Pharmacol (2008) 154(7):1457-1464.
44. Lynch JJ 3rd, Wilson AW, Hernandez LE, Nelson RA, Marsh KC, Cox BF, Mittelstadt SW: Dose-response effects of solalol on cardiovascular function in conscious, freely moving cynomolgus monkeys. Br J Pharmacol (2008) 154(7):1439-1445.
45. Sugiyama A: Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts. Br J Pharmacol (2008) 154(7):1528-1537.
46. Vos MA: Literature-based evaluation of four "hard endpoint" models for assessing drug-induced torsades de pointes liability. Br J Pharmacol (2008) 154(7):1523-1527.
47. Barros TP, Alderton WK, Reynolds HM, Roach AG, Berghmans S: Zebrafish: An emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery. Br J Pharmacol (2008) 154(7):1400-1413.
48. Mittelstadt SW, Hemenway CL, Craig MP, Hove JR: Evaluation of zebrafish embryos as a model for assessing inhibition of hERG. J Pharmacol Toxicol Methods (2008) 57(2):100-105.
49. Lawrence CL, Pollard CE, Hammond TG, Valentin JP: In vitro models of proarrhythmia. Br J Pharmacol (2008) 154(7):1516-1522.
50. Thai KM, Ecker GF: Predictive models for hERG channel blockers: Ligand-based and structure-based approaches. ChemMedChem (2007) 14(28):3003-3026.
51. Inanobe A, Kamiya N, Murakami S, Fukunishi Y, Nakamura H, Kurachi Y: In silico prediction of chemical block of human ether-a-go-gorelated gene (hERG) K+ current. J Physiol Sci (2008) 58(7):459-470.
52. Kleber AG, Rudy Y: Basic mechanisms of cardiac impulse propagation and associated arrhythmias. Physiol Rev (2004) 84(2):431-488.
53. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by α1- adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol (2004) 369(5):462-472.
54. Thomas D, Bloehs R, Koschny R, Ficker E, Sykora J, Kiehn J, Schlömer K, Gierten J, Kathöfer S, Zitron E, Scholz EP et al: Doxazosin induces apoptosis of cells expressing hERG K+ channels. Eur J Pharmacol (2008) 579(1-3):98-103.
55. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA (2000) 283(15):1967-1975.
56. González-Juanatey JR, Iglesias MJ, Alcaide C, Piñeiro R, Lago F: Doxazosin induces apoptosis in cardiomyocytes cultured in vitro by a mechanism that is independent of α1-adrenergic blockade. Circulation (2003) 107(1):127-131.
57. Smith GA, Tsui HW, Newell EW, Jiang X, Zhu XP, Tsui FW, Schlichter LC: Functional up-regulation of hERG K+ channels in neoplastic hematopoietic cells. J Biol Chem (2002) 277(21):18528-18534.
58. Wang H, Zhang Y, Cao L, Han H, Wang J, Yang B, Nattel S, Wang Z: hERG K+ channel, a regulator of tumor cell apoptosis and proliferation. Cancer Res (2002) 62(17):4843-4848.
59. Wang Z: Roles of K+ channels in regulating tumor cell proliferation and apoptosis. Pflugers Arch Eur J Physiol (2004) 448(3):274-286.
60. Towarta R, Linders JTM, Hermans AN, Rohrbacher J, van der Linde HJ, Ercken M, Cik M, Roevens P, Teisman A, Gallacher DJ: Blockade of the IKs potassium channel: An overlooked cardiovascular liability in drug safety screening? J Pharmacol Toxicol Methods (2009) 60(1):1-10.
61. Scherer D, Hassel D, Bloehs R, Zitron E, von Löwenstern K, Seyler C, Thomas D, Konrad F, Bürgers HF, Seemann G, Rottbauer W et al: Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents. Br J Pharmacol (2009) 156(2):226-236.
62. Sun H, Liu X, Xiong Q, Shikano S, Li M: Chronic inhibition of cardiac Kir2.1 and hERG potassium channels by celastrol with dual effects on both ion conductivity and protein trafficking. J Biol Chem (2006) 281(9):5877-5884.
63. Gu DF, Li XL, Qi ZP, Shi SS, Hu MQ, Liu DM, She CB, Lv YJ, Li BX, Yang BF: Blockade of hERG K+ channels by isoquinoline alkaloid neferine in the stable transfected HEK293 cells. Naunyn Schmiedebergs Arch Pharmacol (2009) 380(2):143-151.
64. Rajamani S, Shryock JC, Belardinelli L: Rapid kinetic interactions of ranolazine with hERG K+ current. J Cardiovasc Pharmacol (2008) 51(6):581-589.
65. Zhao XL, Qi ZP, Fang C, Chen MH, Lv YJ, Li BX, Yang BF: hERG K+ channel blockade by the novel antiviral drug sophocarpine. Biol Pharm Bull (2008) 31(4):627-632.
66. Zhao XL, Gu DF, Qi ZP, Chen MH, Wei T, Li BX, Yang BF: Comparative effects of sophocarpine and sophoridine on hERG K+ channel. Eur J Pharmacol (2009) 607(1-3):15-22.